Abstract
Type 2 diabetes is one of the leading causes of death in the U.S. Type 2 Diabetes is the most generic form of diabetes, where your body suffers from insulin resistance. Islet Amyloid Polypeptide (IAPP) is a regulatory peptide which inhibits glucagon and insulin secretion. The aggregation of IAPP is present in pancreatic islet amyloid deposits seen especially in Type 2 diabetes in humans and other mammalian species. Our objective was to see how the changes in IAPP sequence correlates to the toxicity of IAPP on mammalian cells. Here, we focus on dog, cat, and guinea pig IAPP. Molecular techniques such as MTT assay and LDH Cytotoxicity assay were used to test the effect animal IAPP has on HeLa cells. As well as to see the effect mixing human and animal IAPP has on the HeLa cells. MTT assay results showed that the animal IAPP volumes had no significant effect on mammalian cell viability while the human IAPP was consistently toxic to the cells. Cell viability percentages stayed relatively constant despite increasing IAPP volume. In comparison, human IAPP showed a decreasing cell viability trend with increasing IAPP volume. However, when dog IAPP and human IAPP were mixed, cell viability was increased. The same effect occurred with the mixing of cat IAPP and human IAPP. LDH Cytotoxicity assay results showed that percent toxicity increased with increasing IAPP volumes for human, cat and guinea pig. Dog IAPP cell toxicity stayed constant as IAPP volume increased. When dog IAPP and cat IAPP were separately mixed with human IAPP, a decrease in cell toxicity is seen. Mixing guinea pig IAPP with human IAPP had no effect on cell viability or cell toxicity. Further experiments are necessary to determine a correlation between these specific animal IAPPs and cell toxicity.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have